Viral Hepatitis C - Human Genome Sciences: challenging the pegylated interferons

Human Genome Sciences: challenging the pegylated interferons
Pharmaceutical Business Review - Mar 15 8:51 PM
Interim results of a phase II trial of Human Genome Sciences Albuferon in combination with ribavirin showed a significant antiviral effect in non-responders at 48 weeks of treatment. Although its favorable once-monthly dosing puts Albuferon in a strong position to potentially replace pegylated interferon, the drugs success might be delayed by the approval of specific HCV inhibitors.Save to My Web

Schering-Plough and PTC Therapeutics Announce Collaboration for Development of PTC's Preclinical Hepatitis C Compounds
[Press Release] PR Newswire via Yahoo! Finance - Mar 20 5:30 AM
Schering-Plough Corporation and PTC Therapeutics, Inc. today announced that they have entered into an exclusive collaboration and licensing agreement for the development of PTC's preclinical compounds for the oral treatment of hepatitis C virus infection and other viral diseases.Save to My Web

NOVARTIS announces in-licensing of valopicitabine (NM283), a novel first-in- ...
Financial.de - Mar 28 11:21 PM
Basel, Switzerland, March 29, 2006 - Novartis ( News / Kurs / Chart / Board ) announced today that it has exercised its option from Idenix Pharmaceuticals to in-license the late-stage development compound valopicitabine (NM283) for the treatment of hepatitis C, a condition estimated to affect more than 170 million people worldwide and a major cause of liver disease.Save to My Web

Coley Pharmaceutical Group Announces Top-line Data from a Clinical Study of Actilon(TM) for Hepatitis C
[Press Release] PR Newswire via Yahoo! Finance - Mar 21 5:30 AM
Coley Pharmaceutical Group, Inc. today announced positive top-line interim data from the company's twelve-week, randomized, controlled clinical study of Actilon in combinations with pegylated interferon and/or ribavirin for the treatment of chronic Hepatitis C virus in the relapsed subset of treatment experienced patients.Save to My Web

XTL Biopharmaceuticals Ltd. Raises $28 Million in Private Equity Transaction With Institutional Investors
RedNova - Mar 20 3:01 AM
NEW YORK, March 20 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd.Save to My Web

Viral Hepatitis C - Novartis Licenses Hep C Drug

Novartis Licenses Hep C Drug
Red Herring - Novartis said Wednesday it has licensed a late-stage compound developed by Idenix Pharmaceuticals to treat the liver infection hepatitis C, marking an ambition move by the Swiss pharmaceutical giant to enter an already competitive market. Idenix has

Coffee and Me
Sacramento Union - ane called President Nixon a warmonger for sending U.S. troops against the Vietnamese in their sanctuary of Cambodia. Nixon replied that Fonda and kind were a bunch of bums. At a Washington rally Fonda welcomed her fellow bums

Daily Planner: Monday
Chico Enterprise-Record - BLOOD DRIVE: Donor hours 8 a.m.-1 p.m. Saturday; 8 a.m.-3 p.m. Monday and Wednesday; 11 a.m.-6 p.m. Tuesday and Thursday; 7 a.m.-2 p.m. Friday. BloodSource, 555 Rio Lindo Ave., Chico. 893-5433. Weekly. BUTTE COUNTY COORDINATING COUNCIL: 11:15 a.m.-1

New CDs By Saxophonists Eric Alexander, Don Braden & Vincent Herring
PRWeb - New CDs showcasing the instrumental virtuosity of a trio of saxophonists at the forefront of the contemporary international jazz scene bring to nine the number of mainstream jazz titles HighNote has released to date in 2006 and should solidify the

Ask the Doctor: Hepatitis C sufferers may get unwarranted stigma
Fort Wayne News-Sentinel - Several months ago, I published a column on hepatitis, written by Dr. Alfred McNair, who is a board-certified gastroenterologist on the Coast. I've never received as many responses to an article as I received to that one. Some were congratulatory and

Viral Hepatitis C - HepCWebWarriors : Fight hepatitis C with awareness & knowledge! Web Warriors scour the web for stellar Hep C sites ...

HepCWebWarriors : Fight hepatitis C with awareness & knowledge! Web Warriors scour the web for stellar Hep C sites ...
HepCWebWarriors: Fight hepatitis C with awareness & knowledge! Web Warriors scour the web for stellar Hep C sites and share their discoveries. ... spend time researching the web for info on Hep C. We are "Web Warriors". We fight the ... therapy, Inspirational sites,Hep C protocols, Hep C success stories, Hep C celebrities ...

Daniel's Hepatitis C Web Site
Provides information, and support, and links.

Hepatitis Central
Information and support for people with dealing with Hepatitis C (HCV) infection.

Hep C Connections (PDF)
... By Elizabeth Matson, Hep C Connection Social Work Intern ... breakfast while learning about hepatitis C at Hep C. Connection's third annual legislative breakfast held at the ...

Viral Hepatitis C - CLASSES

CLASSES
The Pueblo Chieftain - Mar 05 6:57 AM
Beginning oil painting classes will be held from noon to 3 p.m. each Saturday at Red Raven Studio. For information, call 545-2795 or e-mail info@artaspens.com . * * * The evening support group of the National MS Society , Colorado Chapter, southern office, will meet at 7 p.m. Tuesday at Wesley United Methodist Church, 85 Stanford Ave. People with MS, their families and friSave to My Web

GoGirlsMusic.com Names HepCAware.org the Official Charity of the 2006 'Invasion of The GoGirls'
[Press Release] PR Web - Mar 04 12:10 AM
GoGirlsMusic.com and HepCAware.org are working together again to raise awareness of hepatitis C. Kelly Zirbes, founder of HepCAware.org and a GoGirls member, has received a lot of support from Madalyn Sklar, founder of GoGirls, including a GoGirlsMusic Sponsorship for her annual "Hep C Aware -- The Internet Telethon". This year it was business as usual for Sklar to offer an opportunity for Kelly Save to My Web

Schering-Plough, PTC Therapeutics team up for development of PTC's preclinical hep C compounds
PharmaBiz - Mar 21 9:43 PM
Schering-Plough Corporation and PTC Therapeutics, Inc. (PTC) have entered into an exclusive collaboration and licensing agreement for the development of PTC's preclinical compounds for the oral treatment of hepatitis C virus (HCV) infection and other viral diseases.Save to My Web

WNC Calendar
Asheville Citizen-Times - Mar 17 9:16 PM
MIDDLE SCHOOL MADNESS AT YMCA REUTER FAMILY CENTER: 7 to 11 p.m. for grades six to eight. $5 for members and $10 for friends. Swimming, rock climbing and more. Call 651-9622.Save to My Web

Ask the Doctor: Hepatitis C Sufferers May Get Unwarranted Stigma
RedNova - Mar 20 1:18 PM
Dear Readers: Several months ago, I published a column on hepatitis, written by Dr. Alfred McNair, who is a board-certified gastroenterologist on the Coast. I've never received as many responses to an article as I received to that one.Save to My Web

Viral Hepatitis C - Idenix Provides Update on Clinical Development of Valopicitabine (NM283) for the Treatment of Hepatitis C

Idenix Provides Update on Clinical Development of Valopicitabine (NM283) for the Treatment of Hepatitis C
FinanzNachrichten - Mar 23 2:09 PM
CAMBRIDGE, Mass., March 23 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, ( Nachrichten ) Inc. , a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases, announced today an update on its clinical development program for valopicitabine (NM283) for the treatment of hepatitis C. Idenix has Save to My Web

Govt accused of breaking promise to pursue drug firms
Irish Examiner - Mar 23 2:51 AM
The Irish Haemophilia Society (IHS) is reportedly accusing the Government of failing to pursue pharmaceutical firms that sold contaminated products to the Irish Blood Transfusion Service.Save to My Web

Hepatitis C Victims 'Could Hit 1m'
RedNova - Mar 23 5:33 AM
THERE could be five times the number of people infected with hepatitis C than current estimates suggest, an expert warned yesterday.Save to My Web

BioScrip to Report Fourth Quarter and Year End 2005 Earnings on March 29
[Press Release] Business Wire via Yahoo! Finance - Mar 27 9:59 AM
ELMSFORD, N.Y.----March 27, 2006--BioScrip, Inc. announced today that it will report its fourth quarter and year end earnings for the period ended December 31, 2005, before market open on March 29, 2006.Save to My Web

Human Genome Sciences Shares Fall After Early Hepatitis C Treatment Data Released
Money Sense - Mar 14 8:39 AM
Shares of Human Genome Sciences Inc. dropped Tuesday as investors showed displeasure with preliminary mid-stage results showing the biotech company's interferon product produced comparable results to the standard of care for new hepatitis C patients.Save to My Web

Viral Hepatitis C - Body parts scandal raises critical questions

Body parts scandal raises critical questions
Burlington Free Press - The list of Vermonters affected by a national scandal involving stolen body parts continues to grow, with three Vermont hospitals and three dental surgery facilities notified as recently as Monday of patients who might have received questionable

Antibodies Neutralizing Peginterferon Alfa during Retreatment of
New England Journal of Medicine - To the Editor: Peginterferons are widely used to treat chronic hepatitis C virus (HCV) infection, an important cause of liver cirrhosis and hepatocellular carcinoma. 1 , 2 , 3 , 4 We describe a patient who did not have a virologic response to

Human Genome tumbles on mixed drug data
Investors Business Daily - BOSTON (MarketWatch) -- Human Genome Sciences shares tumbled Tuesday following the release of mixed Phase II clinical data for its biologic drug candidate to treat hepatitis C, Albuferon. Shares of Human Genome sank 20% to close at $10.89. In a

Screening test available to detect an antibody to hepatitis C
Inside Bay Area - This is the fourth in a series of columns on medical conditions that are hard to diagnose in women. To read last week's column, visit insidebayarea.com, click on "health" and then click on the headline for "Knowing the warning signs for cervical

CytoDyn CEO Explains Company's Strategy to Prevent Drug-Resistant
Financial News USA - City of Industry, CA --(www.FinancialNewsUSA.com)-- 03/21/2006 - Pharmaceuticals industry news provided by Financial News USA (OTC: FNWU) A recent meeting of the New Mexico Biotechnology & Biomedical Association featured a talk by Allen D. Allen, CEO

Viral Hepatitis C - World J Gastroenterol

World J Gastroenterol
Lamivudine does not increase the efficacy of interferon in the treatment of mutant type chronic viral heaptitis B. World J Gastroenterol 2002 October ...

viral hepatitis. need advice about viral hepatitis?
... viral hepatiti new items hepatits. viral hpeatitis detailed information hepatiti viral heaptitis purchase with paypal hpeatitis, viral heptaitis order ...

[Behavior of Owren's Thrombotest in acute viral hepatitis, viral ...
[Behavior of Owren's Thrombotest in acute viral hepatitis, viral heaptitis of prolonged duration, acute post-hepatitis atrophy of the liver and its relation ...

Viral Hepatitis C - Hepatitis C

Hepatitis C
Title: Hepatitis CCategory: Diseases and ConditionsCreated: 12/31/1997Last Editorial Review: 9/17/2005

A Breakthrough Discovery for Hepatitis C
The state of Florida has recently produced a study illuminating the replication and mutation of the Hepatitis C virus. This kind of progress represents a giant leap forward in tracking this persistent virus, which likely means more accurate and efficient...

Liver Cancer, Hepatitis C Connection Gets Clearer
Title: Liver Cancer, Hepatitis C Connection Gets ClearerCategory: Health NewsCreated: 12/8/2005 1:59:00 AMLast Editorial Review: 12/8/2005 1:58:50 AM

SCH 503034 Jumps on the Fast Track
Schering-Plough's oral HCV protease inhibitor, SCH 503034, is in phase II trials, and may make for a better combination with Peg-intron. Check-in with us regularly, as we will be keeping close tabs on this development....